{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:26Z","timestamp":1790716586965,"version":"4.1.0"},"reference-count":169,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02856","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:33:51Z","timestamp":1576852431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Let\u2019s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Dalma","family":"Deak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina-Andreea","family":"Zimta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancuta","family":"Jurj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ghiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Pasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Teodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Antohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Onaciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Berindan-Neagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobe","family":"Petrushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Turcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Iluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Selicean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Danaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"JCO"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia. (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrclinonc.2017.42","article-title":"New standard for relapsed ALL","volume":"14","author":"Hutchinson","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the high-hanging fruit","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","article-title":"Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia","volume":"9","author":"Tomuleasa","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16557","DOI":"10.18632\/oncotarget.24637","article-title":"Genetically enhanced T lymphocytes and the intensive care unit","volume":"9","author":"Tat","year":"2018","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leukemia Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.omtn.2019.05.032","article-title":"Activation of necroptosis by engineered self tumor-derived exosomes loaded with CRISPR\/Cas9","volume":"17","author":"Gulei","year":"2019","journal-title":"Mol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737159.2019.1568242","article-title":"CRISPR-based RNA editing: diagnostic applications and therapeutic options","volume":"19","author":"Gulei","year":"2019","journal-title":"Exp Rev Mol Diagnost"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory b-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase ii, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"JCO"},{"key":"B21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S2352-4642(18)30066-X","article-title":"Global efforts toward the cure of childhood acute lymphoblastic leukaemia","volume":"2","author":"Pui","year":"2018","journal-title":"Lancet Child Adolescent Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2352-4642(18)30023-3","article-title":"Assessing the feasibility and validity of the Toronto childhood cancer stage guidelines: a population-based registry study","volume":"2","author":"Aitken","year":"2018","journal-title":"Lancet Child Adolescent Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314. (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995\u20132009, by subtype, age, and sex. (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/asheducation-2018.1.146","article-title":"Long-term complications in adolescent and young adult leukemia survivors","volume":"2018","author":"Baker","year":"2018","journal-title":"Hematology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia. (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (EBMT)","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs. adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bjh.15761","article-title":"Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: the NOPHO ALL2008 experience","volume":"184","author":"Ifversen","year":"2019","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/gcc.22664","article-title":"Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: a single center experience of 296 cases","volume":"57","author":"Olsson","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ejh.12896","article-title":"Age but not Philadelphia positivity impairs outcome in older\/elderly patients with acute lymphoblastic leukemia in Sweden","volume":"99","author":"Kozlowski","year":"2017","journal-title":"Eur J Haematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","article-title":"Acute lymphoblastic leukemia, Version 2.2015","volume":"13","author":"Alvarnas","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3109\/10428194.2016.1141407","article-title":"B-cell acute lymphoblastic leukemia with mature phenotype and MLL rearrangement: report of five new cases and review of the literature","volume":"57","author":"Sajaroff","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/leu.2010.284","article-title":"Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement","volume":"25","author":"Bueno","year":"2011","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11864-019-0603-z","article-title":"Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"20","author":"Abou Dalle","year":"2019","journal-title":"Curr Treat Options in Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/sj.leu.2401413","article-title":"Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) \u2013 a report of the Children's Cancer Group","volume":"13","author":"Heerema","year":"1999","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","article-title":"Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Irving","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1080\/10428194.2018.1509318","article-title":"Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients","volume":"60","author":"Miller","year":"2019","journal-title":"Leukemia Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3324\/haematol.2018.196055","article-title":"Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"104","author":"Fedullo","year":"2019","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1002\/cncr.30262","article-title":"Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Day 14 Bone Marrow Blasts in ALL","volume":"122","author":"Short","year":"2016","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2017.06.010","article-title":"The Dana Farber consortium protocol. (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients < 50 Y. Single institution experience","volume":"60","author":"Alabdulwahab","year":"2017","journal-title":"Leukemia Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis: HCVAD Plus Ponatinib or Dasatinib for Ph+ ALL","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jconrel.2016.07.035","article-title":"Nanomedicine approaches in acute lymphoblastic leukemia","volume":"238","author":"Tatar","year":"2016","journal-title":"J Contro Release"},{"key":"B49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.clml.2018.03.014","article-title":"Society of Hematologic Oncology. (SOHO) State of the Art Updates and Next Questions\u2014Treatment of ALL","volume":"18","author":"Chiaretti","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2018.12.007","article-title":"Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with philadelphia chromosome\u2013positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era","volume":"25","author":"Xue","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bbmt.2016.11.008","article-title":"Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia","volume":"23","author":"Srour","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2014.09.009","article-title":"No donor? Consider a haploidentical transplant","volume":"29","author":"Ciurea","year":"2015","journal-title":"Blood Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/bloodadvances.2018021899","article-title":"Is a matched unrelated donor search needed for all allogeneic transplant candidates?","volume":"2","author":"Ciurea","year":"2018","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cll.2017.07.005","article-title":"B lymphoblastic leukemia minimal residual disease assessment by flow cytometric analysis","volume":"37","author":"Shaver","year":"2017","journal-title":"Clin Lab Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11912-017-0565-x","article-title":"Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat it","volume":"19","author":"Short","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/10408363.2018.1463508","article-title":"Minimal residual disease in chronic lymphocytic leukemia: a consensus paper that presents the clinical impact of the presently available laboratory approaches","volume":"55","author":"Tomuleasa","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cyto.b.21766","article-title":"Detection of minimal residual disease in B cell acute lymphoblastic leukemia using an eight-color tube with dried antibody reagents","volume":"96","author":"Bouriche","year":"2019","journal-title":"Cytometry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cncr.30264","article-title":"Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia: MRD in Relapsed\/Refractory ALL","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/jcm6070066","article-title":"When less is good, is none better? the prognostic and therapeutic significance of peri-transplant minimal residual disease assessment in pediatric acute lymphoblastic leukemia","volume":"6","author":"Lamble","year":"2017","journal-title":"JCM"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1186\/s12885-018-5002-5","article-title":"Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey","volume":"18","author":"Pigneux","year":"2018","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia. (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council. (MRC) UKALLXII\/Eastern Cooperative Oncology Group. (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine Nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/asheducation-2018.1.9","article-title":"Antibody-based therapies in patients with acute lymphoblastic leukemia","volume":"2018","author":"Dinner","year":"2018","journal-title":"Hematology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.4049\/jimmunol.1501843","article-title":"Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood","volume":"196","author":"Qu\u00e1ch","year":"2016","journal-title":"JI"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1073\/pnas.1814213116","article-title":"Signatures of selection in the human antibody repertoire: selective sweeps, competing subclones, and neutral drift","volume":"116","author":"Horns","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vacc Immunotherapeut"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.4049\/jimmunol.1402942","article-title":"Localized store-operated calcium influx represses CD95-dependent apoptotic effects of rituximab in non-hodgkin B lymphomas","volume":"195","author":"Vacher","year":"2015","journal-title":"JI"},{"key":"B71","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00424-007-0258-7","article-title":"An intermediate-conductance Ca2+-activated K+ channel mediates B lymphoma cell cycle progression induced by serum","volume":"454","author":"Wang","year":"2007","journal-title":"Pflugers Arch"},{"key":"B72","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1186\/s12885-018-4817-4","article-title":"The efficacy and safety of anti-CD19\/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"105397","DOI":"10.18632\/oncotarget.22207","article-title":"CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/jjco\/hyx126","article-title":"CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy","volume":"47","author":"Isshiki","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","article-title":"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell\u2013mediated antibody-dependent cellular cytotoxicity","volume":"121","author":"Rudnicka","year":"2013","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4161\/mabs.1.4.8895","article-title":"Ofatumumab","volume":"1","author":"Zhang","year":"2009","journal-title":"mAbs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/nbt0114-6b","article-title":"Genentech's glyco-engineered antibody to succeed Rituxan","volume":"32","author":"Ratner","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B78","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Ere\u00f1o-Orbea","year":"2017","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura: Rituximab Chimeric Anti-CD20 MAB Treatment for Adult Refractory ITP","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/cncr.28948","article-title":"Magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab","volume":"120","author":"Dima","year":"2014","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5045\/br.2017.52.3.159","article-title":"Advances in the treatment of newly diagnosed primary central nervous system lymphomas","volume":"52","author":"Qian","year":"2017","journal-title":"Blood Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14712598.2018.1425389","article-title":"Rituximab in the management of acute lymphoblastic leukemia","volume":"18","author":"Levato","year":"2018","journal-title":"Exp Opin Biol Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.hoc.2009.07.005","article-title":"Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia","volume":"23","author":"Thomas","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-0056","article-title":"Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma","volume":"21","author":"Barth","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101. (Obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Therapeut"},{"key":"B89","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1060028017736539","article-title":"The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia","volume":"52","author":"Horvat","year":"2018","journal-title":"Ann Pharmacother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clinic Proc"},{"key":"B91","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1517\/14712598.2014.948414","article-title":"Update on obinutuzumab in the treatment of B-cell malignancies","volume":"14","author":"Illidge","year":"2014","journal-title":"Exp Opin Biol Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.13764","article-title":"Obinutuzumab. (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive\/-resistant Burkitt lymphoma. (BL) and precursor B-acute lymphoblastic leukaemia","volume":"171","author":"Awasthi","year":"2015","journal-title":"Br J Haematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","article-title":"Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia","volume":"10","author":"Wei","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/ejh.12154","article-title":"Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study","volume":"91","author":"Gorin","year":"2013","journal-title":"Eur J Haematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14728214.2017.1366447","article-title":"Emerging antibody-drug conjugates for treating lymphoid malignancies","volume":"22","author":"Wolska-Washer","year":"2017","journal-title":"Exp Opin Emerg Drugs"},{"key":"B99","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjh.13205","article-title":"Current status of antibody therapy in ALL","volume":"168","author":"Ai","year":"2015","journal-title":"Br J Haematol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"M\u00f8lh\u00f8j","year":"2007","journal-title":"Mol Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/14712598.2017.1387244","article-title":"Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia","volume":"17","author":"Tvito","year":"2017","journal-title":"Exp Opin Biol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1358\/dot.2017.53.12.2737934","article-title":"Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia","volume":"53","author":"Choudhry","year":"2017","journal-title":"Drugs Today"},{"key":"B103","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bph.13697","article-title":"Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells: Pharmacology of anti-CD22 and anti-CD79b ADCs","volume":"174","author":"Fuh","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2174\/0929867324666170113105733","article-title":"Epratuzumab and Blinatumomab as therapeutic antibodies for treatment of pediatric acute lymphoblastic leukemia: current status and future perspectives","volume":"24","author":"Franca","year":"2017","journal-title":"CMC"},{"key":"B108","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/1535-7163.MCT-11-0632","article-title":"Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies","volume":"11","author":"Sharkey","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"B110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jim.2016.05.007","article-title":"An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox","volume":"435","author":"Schneider","year":"2016","journal-title":"J Immunol Methods"},{"key":"B111","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jps.23343","article-title":"Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys","volume":"102","author":"Wang","year":"2013","journal-title":"J Pharmaceut Sci"},{"key":"B112","doi-asserted-by":"publisher","first-page":"11311","DOI":"10.1073\/pnas.0804851105","article-title":"An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes","volume":"105","author":"Onda","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B113","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4161\/mabs.3.5.17228","article-title":"The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan","volume":"3","author":"Kawa","year":"2011","journal-title":"mAbs"},{"key":"B114","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1073\/pnas.1102746108","article-title":"Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes","volume":"108","author":"Onda","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B115","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.leu.2401779","article-title":"Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro","volume":"14","author":"Herrera","year":"2000","journal-title":"Leukemia"},{"key":"B119","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/sj.leu.2402790","article-title":"Treatment of SCID\/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins","volume":"17","author":"Herrera","year":"2003","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/MPH.0b013e3181bdf211","article-title":"A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia: J Pediatr Hematol Oncol","volume":"31","author":"Herrera","year":"2009"},{"key":"B121","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1150648","article-title":"Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia","volume":"319","author":"Hong","year":"2008","journal-title":"Science"},{"key":"B122","first-page":"61","article-title":"Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma","volume":"19","author":"Tomuleasa","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"B123","first-page":"583","article-title":"Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells","volume":"15","author":"Tomuleasa","year":"2010","journal-title":"J BUON"},{"key":"B124","first-page":"189","article-title":"Stem-like cells in colorectal oncology","volume":"49","author":"Tomuleasa","year":"2011","journal-title":"Rom J Intern Med"},{"key":"B125","first-page":"319","article-title":"The axis of evil in the fight against cancer","volume":"49","author":"Petrushev","year":"2011","journal-title":"Rom J Intern Med"},{"key":"B126","first-page":"758","article-title":"Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme","volume":"15","author":"Tomuleasa","year":"2010","journal-title":"J Buon"},{"key":"B127","first-page":"16","article-title":"Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy","volume":"16","author":"Florian","year":"2011","journal-title":"J Buon"},{"key":"B128","first-page":"230","article-title":"The colorectal cancer stem-like cell hypothesis: a pathologist's point of view","volume":"17","author":"Susman","year":"2012","journal-title":"J BUON"},{"key":"B129","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.3748\/wjg.v20.i15.4128","article-title":"Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma","volume":"20","author":"Rani","year":"2014","journal-title":"WJG"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell\u2013engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"JCO"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3109\/10428194.2012.679267","article-title":"Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin. (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia","volume":"53","author":"Barta","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","article-title":"The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models","volume":"104","author":"Hicks","year":"2019","journal-title":"Haematologica"},{"key":"B134","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2015.12.004","article-title":"A phase II study of coltuximab ravtansine. (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2016","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B135","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/acs.molpharmaceut.5b00175","article-title":"Design of coltuximab ravtansine, a CD19-targeting antibody\u2013drug conjugate. (ADC) for the treatment of B-cell malignancies: structure\u2013activity relationships and preclinical evaluation","volume":"12","author":"Hong","year":"2015","journal-title":"Mol Pharmaceut"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2017-04-779389","article-title":"Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies","volume":"130","author":"Ryan","year":"2017","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer\u2013containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"B139","first-page":"732","article-title":"Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma","volume":"16","author":"Kahl","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/CPAA.S42689","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"CPAA"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e1008339","DOI":"10.1080\/2162402X.2015.1008339","article-title":"Are BiTEs the missing link in cancer therapy?","volume":"4","author":"Suryadevara","year":"2015","journal-title":"OncoImmunology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager. (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B143","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620716640422","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Benjamin","year":"2016","journal-title":"Therapeut Adv Hematol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"B145","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit\u2013Risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"key":"B146","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv"},{"key":"B148","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager. (BiTE\u00ae) antibody construct, in patients with minimal residual disease b-precursor acute lymphoblastic leukemia. (ALL)","volume":"124","author":"Goekbuget","year":"2014","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager. (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/17474086.2017.1396890","article-title":"Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia","volume":"10","author":"Ribera","year":"2017","journal-title":"Exp Rev Hematol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/asheducation-2018.1.25","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2018","author":"Jain","year":"2018","journal-title":"Hematology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager. (BiTE) Antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"JCO"},{"key":"B154","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"key":"B156","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1182\/blood-2012-10-460394","article-title":"Toward victory in adult ALL: blinatumomab joins in","volume":"120","author":"Bassan","year":"2012","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MOP.0b013e32834ec9c1","article-title":"Hemophagocytic lymphohistiocytosis: updates and evolving concepts","volume":"24","author":"Risma","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"B158","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/jmg.2007.052670","article-title":"Genotype phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations","volume":"45","author":"Trizzino","year":"2007","journal-title":"J Med Genet"},{"key":"B160","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaneurol.2019.0658","article-title":"Association of closed-loop brain stimulation neurophysiological features with seizure control among patients with focal epilepsy","volume":"76","author":"Kokkinos","year":"2019","journal-title":"JAMA Neurol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/541157c","article-title":"Funds to help Eastern Europe close the gap","volume":"541","author":"Berce","year":"2017","journal-title":"Nature"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/jcm8081175","article-title":"Approach to the adult acute lymphoblastic leukemia patient","volume":"8","author":"Sas","year":"2019","journal-title":"JCM"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1001\/jamaneurol.2019.2384","article-title":"Tackling epilepsy with high-definition precision medicine: a review","volume":"76","author":"Kearney","year":"2019","journal-title":"JAMA Neurol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e191439","DOI":"10.1001\/jamapediatrics.2019.1439","article-title":"Low-value diagnostic imaging use in the pediatric emergency department in the United States and Canada","volume":"173","author":"Cohen","year":"2019","journal-title":"JAMA Pediatr"},{"key":"B165","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia. (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"B166","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1470-2045(14)71183-0","article-title":"Blinatumomab: a new era of treatment for adult ALL?","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","article-title":"Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective","volume":"20","author":"Delea","year":"2017","journal-title":"J Med Econ"},{"key":"B169","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/jcm8060884","article-title":"Clinical approach to the patient in critical state following immunotherapy and\/or stem cell transplantation: guideline for the on-call physician","volume":"8","author":"Constantinescu","year":"2019","journal-title":"JCM"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:33:57Z","timestamp":1576852437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":169,"alternative-id":["10.3389\/fimmu.2019.02856"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02856","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"article-number":"2856"}}